Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DPYD and UGT1A1 Genotype-Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant-Specific Impact on Treatment Intensity and Toxicity.

International journal of cancer - 15 Nov 2026

Gambron Martina, Peruzzi Elena, Perfler Samantha, Montico Marcella, Cecchin Riccardo, De Mattia Elena, Spina Michele, Lisanti Camilla, Corsetti Serena, Foltran Luisa, Puglisi Fabio, Roncato Rossana, Cecchin Erika

Abstract excerpt

DPYD and UGT1A1 variants significantly affect fluoropyrimidines and irinotecan safety. While genotype-driven dosing reduces severe toxicity, the impact of individual variants remains incompletely investigated. This retrospective cohort study includes 178 cancer patients with a matched actionable DPYD and/or UGT1A1 genotypes, defined by the presence of guideline-recommended variants (DPYD: rs3918290, DPYD*2A,...

Read the complete abstract on PubMed

Topics

Humans
Glucuronosyltransferase

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Irinotecan

UGT1A1 Enzyme

Female

Dihydrouracil Dehydrogenase (NADP)

Genotype

Retrospective Studies

Middle Aged

Aged

Male

Antineoplastic Combined Chemotherapy Protocols

Neoplasms

Adult

Fluorouracil

Source

Open in PubMed Open full text

Identifiers

PMID: 42266018
DOI: 10.1002/ijc.70580
PMCID: PMC13595455

Genes

DPYD
UGT1A1

Variants

rs56038477
rs55886062
rs67376798
rs8175347

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DPYD and UGT1A1 Genotype-Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant-Specific Impact on Treatment Intensity and Toxicity.PMID 42266018Read ↗

Pharmacogenetic-guided dosing for fluoropyrimidine (DPYD) and irinotecan (UGT1A1*28) chemotherapies for patients with cancer (PACIFIC-PGx): A multicenter clinical trial.Semantic proximity Read ↗

Optimizing fluoropyrimidine therapy: Real‐world impact of DPYD genotype‐based dosing on severe toxicity ratesSemantic proximity Read ↗

Real-world study on fluoropyrimidine-related toxicity outcomes in cancer patients with select DPYD variant alleles that received DPYD genotype-guided dosing.Semantic proximity Read ↗

Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of DPYD Genotype-Guided Therapy with FluoropyrimidinesSemantic proximity Read ↗

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.Semantic proximity Read ↗

Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse eventsSemantic proximity Read ↗

DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol.Semantic proximity Read ↗

DPYD polymorphisms c.496A>G , c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocolsSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.Semantic proximity Read ↗

Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.Semantic proximity Read ↗

Real-World Impact of UGT1A1 Genotype-Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.